10074-cot-10 a new preoperative predictive scoring system for supratentorial newly diagnosed isocitrate dehydrogenase-wild type glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide

Abstract We aimed to evaluate the usefulness of a preoperative predictive score for assessing overall survival in patients with supratentorial newly diagnosed isocitrate dehydrogenase (IDH)-wild type glioblastoma (GBM) treated with radiotherapy plus concomitant and adjuvant temozolomide. In this study, 104 patients with newly diagnosed supratentorial IDH-wild type GBM were enrolled between May 2007 and April 2021. Four prognostic factors were evaluated preoperatively: age, initial symptoms, neutrophil/lymphocyte ratio (NLR), and contact of the tumor with the ventricles on magnetic resonance imaging (MRI). A scoring system of 0-6 points was created, with 2, 1, 2, and 1 points assigned to age > 75 years, no seizure onset, NLR > 2.23, and ventricular c ontact. The median follow-up period after surgery was 15 months (range: 1-146 months). The total score was 0, 1, 2, 3, 4, 5, and 6 points for 6, 6, 18, 15, 43, 6, and 10 patients respectively. Patients with 0-2, 3-4, and 5-6 points were assigned to groups 1, 2, and 3, respectively. The median survival time from surgery was 20 months in the entire cohort and 34, 19, and 10 months in groups 1, 2, and 3, respectively. The three groups showed significant differences in the median survival time (p< 0.001), with lower scores corresponding to longer survival times. We propose a new preoperative prognostic scoring system for newly diagnosed patients with supratentorial IDH-wild GBM. The prognostic information obtained using this system can help determine the intensity of treatment for the patient.